Byetta: second GLP-1 agonist for diabetesIndicated for use in combination with metformin and/or a sulfonylurea to improve glycemic control in adults with type 2 diabetes. Same practice + new system = RESPECTAfter over 27 years of community pharmacy practice, I have decided to switch gears. Drug News: June 2011 Byetta: second GLP-1 agonist for diabetes; Gilenya: first oral disease-modifying drug for MS; Nucynta CR: new opioid for moderate—moderate/severe pain. Canadians support stronger diabetes policy But those with diabetes are not getting the best care, as evidenced by the high rate of hospitalizations Raising the profile of ‘invisible’ illnesses Asthma may carry increased risk of diabetes, heart disease Researcher urges caution in interpreting results Canadian Diabetes Association to launch compassionate use program Initiative assists people with diabetes who have difficulty covering the costs of blood glucose monitoring supplies. A new view of women’s cardiovascular risks Updated guidelines consider long-term risk with wider focus beyond coronary artery disease Value of adiposity measures such as BMI questioned 2011 Canadian hypertension guidelines released Here's what’s new and key points that remain unchanged in the 2011 guidelines. First Previous 185 186 187 188 189 Next Last
